Cellectis S.A. (NASDAQ:CLLS) Sees Significant Decrease in Short Interest

Cellectis S.A. (NASDAQ:CLLSGet Free Report) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 679,300 shares, a drop of 6.6% from the February 29th total of 727,500 shares. Based on an average daily trading volume, of 50,500 shares, the short-interest ratio is currently 13.5 days.

Hedge Funds Weigh In On Cellectis

Large investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new position in Cellectis during the 3rd quarter valued at about $30,000. BNP Paribas Financial Markets grew its stake in shares of Cellectis by 44.4% in the 4th quarter. BNP Paribas Financial Markets now owns 15,800 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 4,856 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Cellectis in the 2nd quarter worth approximately $46,000. Balyasny Asset Management LLC acquired a new position in shares of Cellectis in the 3rd quarter worth approximately $42,000. Finally, Envestnet Asset Management Inc. grew its stake in shares of Cellectis by 19.2% in the 1st quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,305 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Stock Performance

Cellectis stock opened at $2.65 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.20 and a quick ratio of 2.20. The company’s 50-day moving average price is $2.74 and its two-hundred day moving average price is $2.51. Cellectis has a 52 week low of $0.96 and a 52 week high of $3.77.

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Featured Stories

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.